Overview
Dihydrotestosterone is a potent androgen formed from testosterone through the action of the 5-alpha reductase enzyme. It is produced mainly in androgen-sensitive tissues such as the prostate, hair follicles, and skin. DHT exerts stronger androgenic effects than testosterone and plays a critical role in male sexual differentiation, pubertal development, prostate growth, and hair follicle regulation. Measurement of serum DHT is useful in evaluating disorders of androgen excess or deficiency and monitoring therapy that alters androgen metabolism.
Symptoms
Abnormal serum Dihydrotestosterone levels are associated with a variety of clinical features. Elevated levels may lead to male pattern baldness, acne, oily skin, benign prostatic enlargement, and excessive hair growth in women. In children, increased DHT can cause early virilization, while reduced levels may present with delayed puberty, underdeveloped external genitalia, or ambiguous genitalia. Adults with low DHT may experience reduced libido, impaired sexual development, or features of hypogonadism.
Causes
Increased Dihydrotestosterone levels result from enhanced conversion of testosterone by 5-alpha reductase and are seen in conditions such as androgenetic alopecia, benign prostatic hyperplasia, prostate cancer, congenital adrenal hyperplasia, and female hirsutism.
Decreased DHT levels occur in individuals taking 5-alpha reductase inhibitors like finasteride, those with genetic 5-alpha reductase deficiency, hypogonadism, or delayed puberty. Normal or elevated DHT levels may be seen in androgen insensitivity syndrome due to defective androgen receptor response rather than hormone deficiency.
Risk Factors
Risk factors for altered DHT levels include genetic enzyme defects, use of medications affecting androgen metabolism, endocrine disorders, and advancing age. Men are at higher risk for DHT-related prostate and hair follicle disorders, while women with polycystic or adrenal conditions may show features of androgen excess. Family history of androgen-related conditions also increases susceptibility.
Prevention
Although hormonal disorders affecting DHT cannot always be prevented, early evaluation and monitoring help reduce complications. Judicious use of 5-alpha reductase inhibitors, regular follow-up in patients with prostate or hair disorders, and timely diagnosis of congenital enzyme deficiencies are important. Appropriate management of underlying endocrine conditions and therapeutic monitoring of serum DHT levels support effective treatment and improved clinical outcomes.
